Food and Drug Administration (FDA) has approved a new indication for Novo Nordisk's Ozempic (semaglutide) injection 0.5 mg or 1 mg
it also impacts the brain
Contact your GP or prescribing clinician if you experience: Persistent or severe nausea and vomiting that prevents adequate food or fluid intake, particularly if lasting more than 24-48 hours, as this raises concerns about dehydration and nutritional deficiency Severe abdominal pain , especially if sharp, persistent, or located in the upper abdomen radiating to the back, which could indicate pancreatitisa rare but serious adverse effect of GLP-1 receptor agonists mentioned in the Wegovy SmPC [8] [4] Signs of dehydration including dark urine, dizziness, reduced urination, or extreme thirst Rapid or unintended weight loss that exceeds your expected rate Blood in vomit or stools , which requires urgent assessment (call NHS 111 or 999, or attend A&E) Symptoms of gallbladder disease such as severe right upper abdominal pain, particularly after fatty meals, as rapid weight loss can increase gallstone risk (noted in the Wegovy SmPC) [4] [9] Severe constipation with abdominal distension , which could indicate bowel obstruction Dietary intolerances that significantly impact quality of life or nutritional adequacy should also be discussed with your healthcare team
Among these are Ozempic, Wegovy, Mounjaro, and Saxendainjectable medications that have generated global attention due to their effectiveness
